The Clinical Research Program (CRP) at the UNC Lineberger Comprehensive Cancer Center attracts accomplished academic faculty from diverse cancer related clinical disciplines to foster clinical and laboratory linked research. The CRP's Developmental Therapeutics Group (DTG) is CRP's hub, as rt brings together clinical trials faculty with representation from the major disease specific entries to design and implement investigation-initiated clinical trials and correlative science. Over the past 6 years particular strength has been built in Gl, GU, hematologic, melanoma, and thoracic malignancies, as well as Breast Cancer, which is now a second clinical research and translational program. The CRP also integrates translational concepts that emerge from the basic and population sciences, embedding them in human studies research. Our clinical trials oriented group of nationally recognized biostatisticians both design and analyze LCCC CRP studies while having outstanding peer-reviewed funding In clinical trials methodology. The CRP develops and manages investigator initiated, NCI cooperative group, and pharmaceutical company sponsored trials, whenever possible integrating pharmacologic, molecular, genetic, behavioral, and epidemiologic endpoints. Its 71 members come from 11 departments and schools. We integrate science by disease site while including research issues across the spectrum of surgical, radiation, medical, pediatric, and gynecologic oncology, as well as methodology and imaging questions. Our program is providing senior leadership to NCI wrth Drs. Tepper, Goldberg, Socinski and Carey appointed to CTAC steering committees. Program total cost funding in 2009 was $23.0 million, including $6.1 million in NCI funding. In 2004-9, the total number of publications were 1,532;21% of which were intraprogrammatic and 24% were interprogrammatic. Therapeutic Clinical trials accrual rose from 380 to 848 during the last six years. CRP highlights include Breast and Gl SPOREs, emerging efforts in hepatocellular and renal cancers, outstanding genomic array capabilities in multiple cancers, a multi-center DOD grant in prostate cancer, a P-01 focusing on clinical trials methodology, recruitment of a nationally recognized Breast Cancer and Geriatric Oncology researcher, Hy Muss, and studies in individualized therapy, led by new recruit Howard McLeod. The CRP adds value to the UNC LCCC by acting as the human clinical trials conduit and nexus for clinical and scientific studies that serve the whole LCCC membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594134
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$157,095
Indirect Cost
$66,181
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Suzuki, Aussie; Long, Sarah K; Salmon, Edward D (2018) An optimized method for 3D fluorescence co-localization applied to human kinetochore protein architecture. Elife 7:
Mohan, Vishwa; Sullivan, Chelsea S; Guo, Jiami et al. (2018) Temporal Regulation of Dendritic Spines Through NrCAM-Semaphorin3F Receptor Signaling in Developing Cortical Pyramidal Neurons. Cereb Cortex :
Haase, Karen P; Fox, Jaime C; Byrnes, Amy E et al. (2018) Stu2 uses a 15-nm parallel coiled coil for kinetochore localization and concomitant regulation of the mitotic spindle. Mol Biol Cell 29:285-294
Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6
Becker, Silke; Wang, Haibo; Simmons, Aaron B et al. (2018) Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms. Sci Rep 8:2003
Kim, R D; Alberts, S R; Peña, C et al. (2018) Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer 118:462-470
Chiang, Yun-Chen; Park, In-Young; Terzo, Esteban A et al. (2018) SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Res 78:3135-3146
Reuland, Daniel S; Cubillos, Laura; Brenner, Alison T et al. (2018) A pre-post study testing a lung cancer screening decision aid in primary care. BMC Med Inform Decis Mak 18:5
Kornides, Melanie L; McRee, Annie-Laurie; Gilkey, Melissa B (2018) Parents Who Decline HPV Vaccination: Who Later Accepts and Why? Acad Pediatr 18:S37-S43
Ramsingh, Arlene I; Gray, Steven J; Reilly, Andrew et al. (2018) Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. PLoS One 13:e0198154

Showing the most recent 10 out of 1525 publications